N-nitrosamide carcinogenic effect
|
|
5
|
223
|
April 17, 2025
|
Visualization of Categorized Compounds by CPCA
|
|
66
|
8345
|
April 16, 2025
|
N-nitroso-deucravacitinib
|
|
8
|
198
|
April 13, 2025
|
N- nitroso mebendazole
|
|
0
|
58
|
April 13, 2025
|
Primary amines in formation of nitrosamine
|
|
3
|
320
|
April 10, 2025
|
Clobam Nitrosamine Impurity
|
|
0
|
89
|
April 8, 2025
|
Risk mitigation based on DP specifications
|
|
10
|
541
|
April 7, 2025
|
:brazil: Lhasa Brazil Symposium: Aligning Pharma & Regulatory Standards Globally :brazil:
|
|
0
|
105
|
April 3, 2025
|
Evaluation of the nitrosamine impurities of ACE inhibitors using computational, in vitro, and in vivo methods demonstrate no genotoxic potential -Pub
|
|
8
|
497
|
April 2, 2025
|
Health Canada recalled drug products
|
|
0
|
582
|
April 1, 2025
|
Testing of N-nitroso-cinacalcet
|
|
5
|
388
|
March 27, 2025
|
Quantitative Investigation of Nitrosamine Drug Substance-Related Impurities (NDSRIs) Under Artificial Gastric Conditions by Liquid Chromatography–Tandem Mass Spectrometry and Structure–Activity Relationship Analysis -Pub
|
|
0
|
249
|
March 24, 2025
|
The quagmire with the interim limit of nitroso duloxetine
|
|
4
|
450
|
March 24, 2025
|
Chemistry of N-Nitroso Ivacaftor
|
|
10
|
1229
|
March 21, 2025
|
AI limits and CPCA score (O=NN1CCN=C1CCl)
|
|
8
|
338
|
March 17, 2025
|
Analytical procedure development and proposed established conditions: A case study of a mass spectrometry based NDSRI analytical procedure -Pub
|
|
20
|
1898
|
March 12, 2025
|
Is there any possibility to generate the N-Desmethyl Tramadol in formulation?
|
|
5
|
431
|
March 11, 2025
|
N-nitroso Torasemide Impurity formation and control
|
|
27
|
2102
|
March 9, 2025
|
Nitrosamines et énantiomères
|
|
2
|
240
|
February 18, 2025
|
How to calculate the Limit of Nitrosamines from excipients?
|
|
5
|
570
|
February 4, 2025
|
What is CPCA Score for “N-nitroso of 3-Amino-1,2,4-triazole"
|
|
7
|
395
|
January 30, 2025
|
N-nitroso-Duloxetine recall back in the news!
|
|
18
|
3172
|
January 30, 2025
|
Risk Assessment and Management Strategy of Two New Nitrosamine Drug Substance Related Impurities (NDSRIs) in a Pharmaceutical Drug Product for the Treatment of a Rare Disease- from Prediction to Control-Pub
|
|
0
|
439
|
January 29, 2025
|
EMA nitrosamine Q&A Appendix 1 rev.7 published on Dec 13, 2024
|
|
8
|
1594
|
January 27, 2025
|
🛑 N-nitroso Ticagrelor
|
|
16
|
3179
|
January 23, 2025
|
FREE Lhasa Webinar | Nitrosaminas en el horizonte: ¿Está preparado? 🇲🇽
|
|
1
|
227
|
January 22, 2025
|
Control of N-nitrosamine impurities in drug products: Progressing the current CPCA framework and supporting the derivation of robust compound specific Acceptable Intakes-Pub
|
|
10
|
708
|
January 20, 2025
|
Acceptable Intake N-Nitrosobiotin (N-Nitrosamide)
|
|
2
|
224
|
January 13, 2025
|
SCIEX Webinar: Unlocking precision: nitrosamine and NDSRI analysis(16.1.2025 10:30 CET)
|
|
0
|
294
|
January 12, 2025
|
Modeling the Impact of Excipients Selection on Nitrosamine Formation towards Risk Mitigation
|
|
17
|
4213
|
January 10, 2025
|